产品
编 号：F762358
分子式：C17H23N5O4S
分子量：393.46
分子式：C17H23N5O4S
分子量：393.46
产品类型
规格
价格
是否有货
结构图
CAS No: 1430095-30-9
产品详情
生物活性：
JAK3-IN-9 is an orally active JAK3 inhibitor with IC50 value of 1.7 nM. JAK3-IN-9 is highly selective to the JAK3 signal path. JAK3-IN-9 is lowly toxic with high oral bioavailability, shows good anti-arthritis activity. JAK3-IN-9 can be used in autoimmune disease research.
体内研究：
JAK3-IN-9 (compound 11i) (Female Lewis rats; 3, 10 and 30 mg/kg; Oral gavage once daily for 20 days) can selectively inhibit JAK3 cytokine signaling in the primary cells.JAK3-IN-9 (Male DBA1j of 8 to 12-weeks old mice; 1mg/kg, Intravenous injection, Single administration) shows high AUC of 2104 μg/ml, extends t1/2 to 2.56 h and good oral bioavailability of 48%.JAK3-IN-9 (30 mg/kg; Oral gavage once daily for 20 days) suppress paw swelling in a dose-dependent manner with ED50 value of 10 mg/kg.Animal Model: Male DBA1j (8 to 12-weeks old) mice; Female Lewis rats.
Dosage:1, 3, 10 and 30 mg/kg
Administration:I.V, Single administration; IG, once daily for 20 days.
Result:Showed anti-arthritis activity in the CIA mice model.
体外研究：
JAK3-IN-9 (compound 11i) shows high selective inhibition of JAK3 with IC50 value of 1.7 nM .
JAK3-IN-9 is an orally active JAK3 inhibitor with IC50 value of 1.7 nM. JAK3-IN-9 is highly selective to the JAK3 signal path. JAK3-IN-9 is lowly toxic with high oral bioavailability, shows good anti-arthritis activity. JAK3-IN-9 can be used in autoimmune disease research.
体内研究：
JAK3-IN-9 (compound 11i) (Female Lewis rats; 3, 10 and 30 mg/kg; Oral gavage once daily for 20 days) can selectively inhibit JAK3 cytokine signaling in the primary cells.JAK3-IN-9 (Male DBA1j of 8 to 12-weeks old mice; 1mg/kg, Intravenous injection, Single administration) shows high AUC of 2104 μg/ml, extends t1/2 to 2.56 h and good oral bioavailability of 48%.JAK3-IN-9 (30 mg/kg; Oral gavage once daily for 20 days) suppress paw swelling in a dose-dependent manner with ED50 value of 10 mg/kg.Animal Model: Male DBA1j (8 to 12-weeks old) mice; Female Lewis rats.
Dosage:1, 3, 10 and 30 mg/kg
Administration:I.V, Single administration; IG, once daily for 20 days.
Result:Showed anti-arthritis activity in the CIA mice model.
体外研究：
JAK3-IN-9 (compound 11i) shows high selective inhibition of JAK3 with IC50 value of 1.7 nM .
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备